NeuroMod Systems Investment Opportunity

NeuroMod Systems represents a unique investment opportunity at the intersection of healthcare services, medical technology, and clinical research. Unlike traditional healthcare investments that focus on either clinic operations or medical device development, NeuroMod Systems has created a vertically integrated platform that combines proven clinical operations, proprietary neuromodulation technology, and two of the largest real-world clinical datasets ever assembled for the treatment of peripheral neuropathy.

​

Today, NeuroMod Systems owns and operates National Neuropathy Center, a multi-location specialty clinic network dedicated to the treatment of peripheral neuropathy and chronic pain conditions. The organization currently generates approximately $14 million in annual revenue through its established clinical operations and has developed a proven model for patient acquisition, treatment delivery, outcomes measurement, and multi-site expansion.

​

At the center of the NeuroMod Systems platform is the NeuroGen Neuromodulation device, a proprietary technology designed to address the underlying physiologic dysfunction associated with peripheral neuropathy. NeuroMod Systems owns both the medical device platform and the intellectual property responsible for programming and treatment delivery, creating a significant competitive advantage and multiple pathways for future commercialization.

​

What differentiates NeuroMod Systems from nearly every other healthcare company in the neuropathy space is the combination of ownership across the entire value chain:

• Ownership of a revenue-generating clinic platform

• Ownership of the medical device technology utilized in treatment

• Ownership of the intellectual property supporting the technology

• Ownership of one of the largest known real-world clinical outcome datasets evaluating neuromodulation therapy for peripheral neuropathy

​

Over the past several years, National Neuropathy Center has collected and analyzed treatment outcomes from thousands of patients treated with NeuroGen Neuromodulation therapy. This effort resulted in a peer-reviewed publication evaluating 3,588 patients and nearly 78,000 treatment records, providing substantial real-world evidence supporting symptom reduction and functional improvement in patients suffering from peripheral neuropathy.

​

This research platform provides NeuroMod Systems with a strategic advantage that extends beyond clinical operations. The data supports physician education, payer engagement, future publications, reimbursement initiatives, regulatory strategy, and continued expansion of the company’s intellectual property portfolio.

​

The NeuroMod Systems growth strategy is built upon expanding its proven clinical model into new markets while simultaneously increasing the utilization and distribution of NeuroGen technology. Capital raised through this offering will be used to accelerate national expansion, establish additional treatment centers, strengthen the company’s technology infrastructure, support continued clinical research, and expand market awareness of neuromodulation-based treatment solutions.

​

For investors, NeuroMod Systems offers exposure to three highly valuable healthcare assets within a single organization:

1. A growing healthcare services company with established revenue and operating history.

2. A proprietary medical technology platform with intellectual property ownership.

3. A clinical evidence and research engine capable of supporting future growth, reimbursement initiatives, and market differentiation.

​

As healthcare continues to shift toward evidence-based, outcomes-driven treatment models, NeuroMod Systems is uniquely positioned to capitalize on the growing demand for non-pharmaceutical solutions for chronic neurological conditions.

​

The Company’s vision is to become the national leader in neuromodulation-based treatment for peripheral neuropathy by combining clinical excellence, proprietary technology, and data-driven medicine into a scalable healthcare platform capable of transforming patient outcomes while creating substantial long-term shareholder value.